AOLS (Aeolus Pharmaceuticals) Ending Cash Position: $0.40 Mil (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aeolus Pharmaceuticals Ending Cash Position?

Aeolus Pharmaceuticals AOLS Ending Cash Position is $0.40 Mil as of Jun. 2017.

Aeolus Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2017 was $0.40 Mil.

Aeolus Pharmaceuticals's quarterly Ending Cash Position declined from Dec. 2016 ($1.90 Mil) to Mar. 2017 ($0.98 Mil) and declined from Mar. 2017 ($0.98 Mil) to Jun. 2017 ($0.40 Mil).

Aeolus Pharmaceuticals's annual Ending Cash Position declined from Sep. 2014 ($1.52 Mil) to Sep. 2015 ($0.09 Mil) but then increased from Sep. 2015 ($0.09 Mil) to Sep. 2016 ($3.16 Mil).

Aeolus Pharmaceuticals Ending Cash Position Related Terms

Aeolus Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Ending Cash Position Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.87 1.52 0.09 3.16

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.76 3.16 1.90 0.98 0.40

Aeolus Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Aeolus Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Sep. 2016 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.094+3.061
=3.16

Aeolus Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2017 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.981+-0.578
=0.40

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.40 Mil mean?
Aeolus Pharmaceuticals (AOLS) has a Ending Cash Position of $0.40 Mil as of Jun. 2017. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Ending Cash Position too high?
Aeolus Pharmaceuticals' current Ending Cash Position is $0.40 Mil.
How does Aeolus Pharmaceuticals' Ending Cash Position compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Ending Cash Position of $0.40 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Ending Cash Position is $0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Ending Cash Position of $0.40 Mil. The current Ending Cash Position is $0.40 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Ending Cash Position is $0.40 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.